When The Company Clock Matters More
Stocks sold off Tuesday as U.S. strikes on Iran lifted oil, while the 10-year Treasury yield rose to 4.79%. Higher energy prices and yields are difficult backdrops for growth stocks, and biotech companies aren’t immune: interest rates affect valuations and capital costs, while risk-off markets can make financing more difficult.
But biotech shares often run on a different clock. Clinical data, regulatory meetings, approvals and partnerships can matter more to an individual company than the direction of the broader market on a given day. That makes the sector a useful place to look for asymmetric opportunities when the tape is hostile—provided the trades are priced with the downside in mind.
New to our alerts? Start here to see how we turn a trade idea into an exact entry, an exit plan and a publicly tracked result.
Recent Winners—And A Pending Loser
That asymmetry has worked in our favor on two recent biotech exits. Our TXG trade returned 380% of its maximum risk, and our CAPR trade returned 138% of its maximum risk.
It doesn’t always work. Our TENX position is still technically open because its September call remains, but the put spread took its full-width loss after the stock collapsed. Barring an extraordinary recovery in that remaining call, TENX will be a loser. That’s exactly why we cap the capital at risk on binary or early-stage biotech ideas.
Multibaggers And Market Watchers
Our first two trades came from our Multibaggers list, the subset of our Market Watchers X list made up of analysts who have posted multiple recent 100%+ winners. One is a commercial-stage gene-editing company with a marketed therapy, a large cash balance and several additional programs approaching milestones. The other supplies cell-engineering technology across many drug-development programs, giving it a more diversified revenue stream than a typical single-asset biotech.
Our third trade came from the broader Market Watchers list. It’s a rare-disease gene-therapy developer with several clinical programs, a regulatory meeting expected later this year and enough cash to fund operations into 2028.
The structures reflect those differences. We’re using defined-risk option combinations for the first and third ideas, while buying shares of the second because its options market is effectively unusable. All three also passed our technical screens, but outside research surfaced the ideas; the technicals confirmed them.
Paid subscribers will find the names, exact entries and pre-set exit plans below.
Today’s First Multibaggers Trade
Commercial gene editing / diversified clinical-pipeline theme.
RSI: 54; Chartmill Technical Rating: 8; Setup Rating: 8; Fundamental Rating: 3.
